We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/1/2019 10:22 | likitorma, I think in this case stakeholders are shareholders, the only other interested party would be the Burnet Institute who will probably receive royalties from each test sold...there are no loan notes that I know of, so no other interested parties.....imo | barrywhit | |
29/1/2019 09:34 | Word of caution: Stakeholders are not necessarily shareholders. | likitorma | |
29/1/2019 09:20 | Good to see the Key shareholders are in constant contact with the company: Colin King, Chief Executive of the Group, commented: "I am pleased to announce that we continue to deliver against our timeline for the VISITECT(R) CD4 Advanced Disease test. I am also encouraged by the outlook for this product as key stakeholders continue to engage with us about the sizeable opportunity once we bring the test to market." | barrywhit | |
29/1/2019 08:28 | At last a positive RNS... | barrywhit | |
29/1/2019 07:42 | Need financial indications. | likitorma | |
29/1/2019 07:33 | Very good progress. | verger | |
28/1/2019 10:49 | You're back after your break Dibs. Good timing on your sale a while back. I've lost track on what's happening with the WHO approval. Do you still have a handle on the timeline? It's been as slow as treacle while you were away, though you missed the ex-chairman trying to throw his weight around. | gwr7 | |
25/1/2019 13:38 | OK maybe it was a tree shake | dibs61 | |
24/1/2019 17:19 | I'm guessing Evans went because someone with clout tired of the 3F strategy - Fantasise, Fundraise then Flannel (rinse shareholders and repeat). | gwr7 | |
24/1/2019 14:03 | You are not supposed to say things like that on here | buywell3 | |
24/1/2019 12:24 | Sudden drop today. Suspicious. Placing coming? | dibs61 | |
23/1/2019 10:57 | Moving up. | likitorma | |
22/1/2019 18:33 | The rise started with the £20k purchase(151k @13.25)@ 16.05.... | barrywhit | |
22/1/2019 17:37 | Arthur, I can't imagine anyone is ramping this company..... | barrywhit | |
22/1/2019 17:22 | No idea but I'm all for a bit of excitement at the end of the day, the late trades though are not the norm here, let us see what tomorrow brings if anything? | hyperboreus | |
22/1/2019 17:12 | Nothing to do with me, a bit of an unusual flurry, I wonder if it's being ramped somewhere. | arthur_lame_stocks | |
22/1/2019 17:06 | I am hoping that wasn't you at it again Arthur in the last half hour of trading? 😂 | hyperboreus | |
21/1/2019 18:33 | I would imagine the large holders wanted to see a new broom...the company had not really progressed in a way to satisfy long term shareholders... | barrywhit | |
21/1/2019 17:10 | So do I Arthur, incidentally during your conversation with our former non-exec Chairman did you get the feeling that David Evans resigned due to external pressure being exerted from those 'big shareholders'? It was only last August for instance that he stated: "As we move forward we have a difficult balancing act to maintain in terms of keeping the core business moving along whilst successfully executing our strategic priorities. That challenge should not be underestimated in terms of management stretch but I know that we have a good team here and they are up to that challenge. "I am confident that we can deliver on the goals we have set with emphasis on realising in part value for shareholders. I am also confident that we can deliver on CD4 and I look forward to updating you as we progress throughout the year "Ultimately, we are judged by our results and it may end up being a rather circuitous route to success, but I do believe that after many years of famine shareholders will see some bread in their basket by this time next year. The key thereafter will be to replenish that basket. I am confident we can achieve both." ....then in his interim statement outlook last December: "Our short-term outlook is dominated by our efforts to realise value for Shareholders whilst at the same time successfully accelerating our efforts to commercialise our CD4 offering. The challenges are not inconsequential but I remain confident that in those areas where we can control our own destiny that we will succeed in delivering our objectives. In those areas where we are not masters of our own destiny then, by definition, the outcome will always be less certain. I believe it is best for our statement to reflect that reality as it stands today. Rest assured we will continue to work towards achieving success for all our Stakeholders." ONE WEEK LATER, he resigns, I can only assume that he must have had major misgivings either about the way ODX was heading and/or the increasingly unwelcome influence of the big two! | hyperboreus | |
21/1/2019 16:25 | I bought a few more, I just hope my faith isn't misplaced. | arthur_lame_stocks | |
19/1/2019 13:02 | A bit like a few of us on here Arthur! 😂 | hyperboreus | |
19/1/2019 12:44 | I'm thinking of buying a few more of these, as I believe that the current price doesn't even reflect the value of the Food Intolerance business, let alone the potential of CD4. I also think this is the belief of the two big holders and I think they'll push for a sale of Food Intolerance and maybe a return of some cash with some kept back to invest in CD4. I'm hoping for some good news this year, from speaking to David Evans I got the impression that one of the big shareholders in particular is getting impatient. | arthur_lame_stocks | |
18/1/2019 16:04 | Back to the future with CD4 testing: Improving HIV care in low- and middle-income countries … | barrywhit |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions